Clinical Report: Triggering Tumor-Inherent Innate Immune Responses

Overview

This review discusses the mechanisms of resistance to immune checkpoint blockade (ICB) therapy in cancer treatment and introduces novel strategies to enhance ICB efficacy by inducing tumor-intrinsic innate immune responses.

Background

Immune checkpoint blockade therapy has revolutionized cancer treatment, yet durable responses are limited to a subset of patients, particularly those with solid tumors. Understanding the tumor microenvironment (TME) and its role in ICB resistance is crucial for developing effective therapeutic strategies.

Data Highlights

No numerical data or trial results are provided in the source material.

Key Findings

• The TME is a critical determinant of ICB therapy responsiveness.
• Resistance to ICB is often due to an immunologically 'cold' TME with few infiltrating immune cells.
• Inducing tumor-intrinsic innate immune responses can convert 'cold' tumors to 'hot' tumors.
• Strategies to trigger viral mimicry responses include epigenetic therapies and DNA damage inducers.
• Combining viral mimicry-based strategies with ICB therapy may enhance treatment efficacy.

Clinical Implications

Understanding the mechanisms of TME-mediated resistance is important for the development of combination therapies.

Conclusion

The review highlights the importance of the TME in ICB resistance.

Related Resources & Content

1. Journal of Gastroenterology, 2020 -- Modulating the Immune Environment in Cancers of the Gastrointestinal Tract
2. Roswell Park Comprehensive Cancer Center -- Strategy for Overcoming Resistance to Immunotherapy Unleashes Power of Dendritic Cells
3. Frontiers in Immunology, 2026 -- Immune–tumor cell ligand–receptor axes driving metabolic reprogramming and therapeutic resistance in cancer
4. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors - PMC
5. Innovations in Colorectal Cancer Immunotherapy: An In-Depth Analysis of Approaches, Obstacles, and Future Directions
6. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors - PMC
7. Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors - PubMed
8. First-in-human phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCC | BMC Medicine | Springer Nature Link